22 results on '"Mario J. Garcia"'
Search Results
2. An Overlap Presentation of Pericardial Decompression Syndrome and Stress Cardiomyopathy Following Therapeutic Pericardiocentesis
- Author
-
Roberto C. Cerrud-Rodriguez, MD, Syed Muhammad Ibrahim Rashid, MD, Hussein Shaqra, MD, Ahmad Alkhalil, MD, Mohammed Algodi, MD, Jay J. Chudow, MD, Mario J. Garcia, MD, James M. Tauras, MD, and Giora Weisz, MD
- Subjects
cardiomyopathy ,pericardial decompression syndrome ,pericardial effusion ,stress cardiomyopathy ,systolic dysfunction ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Pericardial decompression syndrome, defined as paradoxical hypotension and pulmonary edema after pericardiocentesis, is a rare complication of pericardiocentesis. Stress cardiomyopathy, caused by excess catecholamine response resulting in left ventricular dysfunction and elevated cardiac enzymes, can overlap with pericardial decompression syndrome, and both might belong to the same spectrum of disease. (Level of Difficulty: Intermediate.)
- Published
- 2020
- Full Text
- View/download PDF
3. Severity of Functional Mitral Regurgitation on Admission for Acute Decompensated Heart Failure Predicts Long‐Term Risk of Rehospitalization and Death
- Author
-
Rachna Kataria, Francesco Castagna, Shivank Madan, Paul Kim, Omar Saeed, Yaw A. Adjepong, Angelos A. Melainis, Cynthia Taub, Mario J. Garcia, Azeem Latib, and Ulrich P. Jorde
- Subjects
acute decompensated heart failure ,functional mitral regurgitation ,sex‐related disparities ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background Functional mitral regurgitation (FMR) has emerged as a therapeutic target in patients with chronic heart failure and left ventricular systolic dysfunction. The significance of FMR in acute decompensated heart failure remains obscure. We systematically investigated the prevalence and clinical significance of FMR on admission in patients admitted with acute decompensated heart failure and left ventricular systolic dysfunction. Methods and Results The study was a single‐center, retrospective review of patients admitted with acute decompensated heart failure and left ventricular systolic dysfunction between 2012 and 2017. Patients were divided into 3 groups of FMR: none/mild, moderate, and moderate‐to‐severe/severe FMR. The primary outcome was 1‐year post‐discharge all‐cause mortality. We also compared these groups for 6‐month heart failure hospitalization rates. Of 2303 patients, 39% (896) were women. Median left ventricular ejection fraction was 25%. Four hundred and fifty‐three (20%) patients had moderate‐to‐severe/severe FMR, which was independently associated with 1‐year all‐cause mortality. Moderate or worse FMR was found in 1210 (53%) patients and was independently associated with 6‐month heart failure hospitalization. Female sex was independently associated with higher severity of FMR. Conclusions More than half of patients hospitalized with acute decompensated heart failure and left ventricular systolic dysfunction had at least moderate FMR, which was associated with increased readmission rates and mortality. Intensified post‐discharge follow‐up should be undertaken to eliminate FMR amenable to pharmacological therapy and enable timely and appropriate intervention for persistent FMR. Further studies are needed to examine sex‐related disparities in FMR.
- Published
- 2022
- Full Text
- View/download PDF
4. Maternal Cardiovascular Outcomes of Pregnancy in Childhood, Adolescent, and Young Adult Cancer Survivors
- Author
-
Neha Bansal, Carol Fernandez Hazim, Sergio Badillo, Sharvari Shyam, Diana Wolfe, Anna E. Bortnick, Mario J. Garcia, Carols J. Rodriguez, and Lili Zhang
- Subjects
cancer survivors ,cardiotoxicity cardiovascular outcomes ,pregnancy ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
This review focuses on the maternal cardiovascular risk and outcomes of pregnancy in childhood, adolescent, and young adult cancer survivors who are achieving survival to their prime reproductive years. Childhood, adolescent, and young adult cancer survivors are a growing population and have increasing needs for reproductive care over decades of life. Female cancer survivors have an overall higher risk of maternal cardiovascular events compared to those without a history of cancer. In female cancer survivors with normal cardiac function before pregnancy, the incidence of new heart failure during pregnancy is low. In survivors with cardiotoxicity prior to pregnancy, the risk of heart failure during and immediately after pregnancy is much higher. We recommend cardiomyopathy surveillance with echocardiography before pregnancy for all female survivors treated with anthracyclines and chest radiation. Survivors with cardiotoxicity prior to pregnancy should be cared for by an expert multidisciplinary team, including obstetrics, cardiology, anesthesia, and specialized nursing, among others.
- Published
- 2022
- Full Text
- View/download PDF
5. Statin Use and In‐Hospital Mortality in Patients With Diabetes Mellitus and COVID‐19
- Author
-
Omar Saeed, Francesco Castagna, Ilir Agalliu, Xiaonan Xue, Snehal R. Patel, Yogita Rochlani, Rachna Kataria, Sasa Vukelic, Daniel B. Sims, Chikezie Alvarez, Mercedes Rivas‐Lasarte, Mario J. Garcia, and Ulrich P. Jorde
- Subjects
COVID‐19 ,diabetes mellitus ,hospitalization ,statin ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background Severe coronavirus disease 2019 (COVID‐19) is characterized by a proinflammatory state with high mortality. Statins have anti‐inflammatory effects and may attenuate the severity of COVID‐19. Methods and Results An observational study of all consecutive adult patients with COVID‐19 admitted to a single center located in Bronx, New York, was conducted from March 1, 2020, to May 2, 2020. Patients were grouped as those who did and those who did not receive a statin, and in‐hospital mortality was compared by competing events regression. In addition, propensity score matching and inverse probability treatment weighting were used in survival models to examine the association between statin use and death during hospitalization. A total of 4252 patients were admitted with COVID‐19. Diabetes mellitus modified the association between statin use and in‐hospital mortality. Patients with diabetes mellitus on a statin (n=983) were older (69±11 versus 67±14 years; P
- Published
- 2020
- Full Text
- View/download PDF
6. Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA
- Author
-
Daniele Massera, Robyn L. McClelland, Bharath Ambale‐Venkatesh, Antoinette S. Gomes, W. Gregory Hundley, Nadine Kawel‐Boehm, Kihei Yoneyama, David S. Owens, Mario J. Garcia, Mark V. Sherrid, Jorge R. Kizer, Joao A. C. Lima, and David A. Bluemke
- Subjects
hypertrophic cardiomyopathy ,magnetic resonance imaging ,population‐based study ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background Hypertrophic cardiomyopathy is defined as unexplained left ventricular (LV) hypertrophy (wall thickness ≥15 mm) and is prevalent in 0.2% of adults (1:500) in population‐based studies using echocardiography. Cardiac magnetic resonance imaging (MRI) allows for more accurate wall thickness measurement across the entire ventricle than echocardiography. The prevalence of unexplained LV hypertrophy by cardiac MRI is unknown. MESA (Multi‐Ethnic Study of Atherosclerosis) recruited individuals without overt cardiovascular disease 45 to 84 years of age. Methods and Results We studied 4972 individuals who underwent measurement of regional LV wall thickness by cardiac MRI as part of the MESA baseline exam. American Heart Association criteria were used to define LV segments. We excluded participants with hypertension, LV dilation (≥95% predicted end‐diastolic volume) or dysfunction (ejection fraction ≤50%), moderate‐to‐severe left‐sided valve lesions by cardiac MRI, severe aortic valve calcification by cardiac computed tomography (aortic valve Agatston calcium score >1200 in women or >2000 in men), obesity (body mass index >35 kg/m2), diabetes mellitus, and current smoking. Sixty‐seven participants (aged 64±10 years, 9% female) had unexplained LV hypertrophy (wall thickness ≥15 mm in at least 2 adjacent LV segments), representing 1.4% (1 in 74) participants, 2.6% of men and 0.2% of women. Prevalence was similar across categories of race/ethnicity. Hypertrophy was focal in 17 (25.4%), intermediate in 44 (65.7%), and diffuse in 5 (7.5%) participants. Conclusions The prevalence of unexplained LV hypertrophy in a population‐based cohort using cardiac MRI was 1.4%. This may have implications for the diagnosis of patients with hypertrophic cardiomyopathy and will require further study.
- Published
- 2019
- Full Text
- View/download PDF
7. Left Atrial Appendage Closure Devices
- Author
-
Jorge Romero, Irving E. Perez, Andrew Krumerman, Mario J. Garcia, and Richard J. Lucariello
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2014
8. Current obstacles in management of hypertensive patients by performance-based care and importance of diagnostic tests.
- Author
-
Fatih Yalçin, Theodore P. Abraham, and Mario J. Garcia
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2015
- Full Text
- View/download PDF
9. Multimodality Imaging of Chronic Ischemia
- Author
-
Kiyotake Ishikawa, Dennis Ladage, Kleopatra Rapti, Leticia Fernandez-Friera, Ana Maria Garcia-Lopez, Javier Sanz, Roger J. Hajjar, Yoshiaki Kawase, and Mario J. Garcia
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Although ischemic cardiomyopathy is commonly caused by chronic obstructive coronary disease, the mechanism of the cause is still under investigation. We present echocardiographic strain, magnetic resonance, and histology findings in a chronic ischemia model in preclinical study. This case illustrates the features of multimodality imaging in chronic obstructive coronary disease and gives us great insight into understanding the mechanism of ischemic cardiomyopathy.
- Published
- 2011
- Full Text
- View/download PDF
10. Registration of real-time 3-D ultrasound images of the heart for novel 3-D stress echocardiography.
- Author
-
Raj Shekhar, Vladimir Zagrodsky, Mario J. Garcia, and James D. Thomas
- Published
- 2004
- Full Text
- View/download PDF
11. Clinical experience and progress of computed tomographic coronary angiography.
- Author
-
Mario J Garcia
- Published
- 2006
- Full Text
- View/download PDF
12. Desarrollo de Monitores de Paciente en Cuba
- Author
-
Mario J. García Valdés
- Subjects
Electrical engineering. Electronics. Nuclear engineering ,TK1-9971 ,Engineering (General). Civil engineering (General) ,TA1-2040 - Abstract
En este trabajo se presenta una comparación entre los diferentes modelos de Monitores de Paciente desarrollados en el ICID. Se describen las características técnicas y de aplicación para entender sus diferencias y semejanzas. La monitorización de Signos Vitales es muy importante en Cuidados Intensivos, en operaciones quirúrgicas y en todos los pacientes bajo observación continua. Los monitores poseen todas las facilidades de operación, almacenamiento, visualización y comunicación requeridas por el personal médico y paramédico. La información que se muestra en la pantalla puede ser gráfica y alfanumérica y se producen alarmas cuando los valores medidos caen fuera del rango seleccionado. Todos los monitores se han diseñado teniendo en cuenta las facilidades para la reparación y el mantenimiento.
- Published
- 2011
- Full Text
- View/download PDF
13. Mejoras del método oscilométrico de medición de la presión no invasiva en el monitor de paciente DOCTUS VI
- Author
-
Daria Vasilievna Kuchinskaia and Mario J. García Valdés
- Subjects
Electrical engineering. Electronics. Nuclear engineering ,TK1-9971 ,Engineering (General). Civil engineering (General) ,TA1-2040 - Abstract
RESUMEN/ABSTRACT Este trabajo recoge algunas mejoras en la medición de la presión arterial de forma no invasiva, por el método oscilométrico tales como: la utilización de servo válvulas para el control del desinflado lento, la detección de casos cuando el brazalete del paciente está suelto, el tratamiento especial a los casos de pacientes con bradicardia y se hace una detección preliminar del movimiento del paciente. Todo esto permite un proceso de medición más eficiente y exacto con rangos de medición amplios. Palabras Claves: Método oscilométrico, Presión no Invasiva, servo válvulas.
- Published
- 2011
- Full Text
- View/download PDF
14. Certeza diagnóstica de la tomografía computarizada multicorte para la detección de la vasculopatía del injerto cardiaco: comparación con angiografía coronaria invasiva y ecografía intravascular Accuracy of multidetector row computed tomography for the detection of transplant vasculopathy: comparison with invasive coronary angiography and intravascular ultrasound
- Author
-
Patricia Carrascosa, Carlos Capuñay, Jorge Carrascosa, Sergio Perrone, Gustavo Lev, Alejandro Deviggiano, Elba Martín López, and Mario J. García
- Subjects
Vasculopatía del injerto cardiaco ,Trasplante ,Tomografía computarizada multicorte ,Ecografía intravascular ,Allograft vasculopathy ,Transplantation ,Multidetector computed tomography ,Intravascular ultrasound ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Objetivo: Evaluar la certeza diagnóstica de la tomografía computarizada multicorte (TCM) en pacientes trasplantados cardiacos para la detección de estenosis coronaria y vasculopatía del injerto cardiaco (VDI) en comparación con la angiografía coronaria (AC) y la ecografía intravascular (EIV), respectivamente. Material y métodos: Diecinueve pacientes trasplantados cardiacos fueron estudiados con angiografía coronaria por TCM entre 7 a 14 días después del cateterismo (AD y EIV). Los estudios se llevaron a cabo con un tomógrafo multicorte de 16 filas. Dos observadores evaluaron en forma ciega los estudios de TCM para la detección de estenosis coronaria >50% y VDI. Resultados: Para la detección de estenosis coronaria >50%, la sensibilidad fue: 80-88% y la especificidad: 98- 99%; para la detección de VDI, 91-96% y 88-98%, respectivamente. Conclusión: En esta serie preliminar, nuestros resultados mostraron que la TCM fue una técnica adecuada para evaluar pacientes trasplantados cardiacos y podría ser una alternativa a la AD y EIV para el seguimiento y control no invasivo de estos pacientes.Objective: To evaluate the diagnostic accuracy of multidetector computed tomography (MDCT) for detection of luminal stenosis and cardiac allograft vasculopathy in comparison with coronary angiography (CA) and intravascular ultrasound (IVUS) respectively. Material and methods: Nineteen cardiac transplant patients scheduled for follow-up CA were included. MDCT coronary angiography was performed using a 16-row CT scanner within 7-14 days after CA and IVUS. Studies were analyzed by independent readers; two observers evaluated the CT datasets for the presence of coronary artery stenosis >50% and allograft vasculopathy. Results: The sensitivity for detecting >50% luminal stenosis was 80-88% and specificity, 98-99% and for detection of cardiac allograft vasculopathy, the sensitivity was 91-96% and specificity, 88-91%. Conclusion: In this preliminary series, our results indicate that MDCT coronary angiography was capable of detecting both significant coronary stenosis as well as diffuse intimal proliferation. This non-invasive procedure could be an alternative to CA and IVUS in the surveillance of heart transplant patients.
- Published
- 2009
15. Relationship between epicardial adipose tissue and coronary atherosclerosis by CCTA in young adults (18–45)
- Author
-
Annalisa Filtz, Daniel Lorenzatti, Andrea Scotti, Pamela Piña, Carol Fernandez-Hazim, Dou Huang, Paul Ippolito, John P Skendelas, Toshiki Kuno, Carlos J Rodriguez, Aldo L Schenone, Azeem Latib, Carl J Lavie, Leslee J. Shaw, Ron Blankstein, Michael D Shapiro, Mario J Garcia, Daniel S Berman, Damini Dey, Salim S Virani, and Leandro Slipczuk
- Subjects
Epicardial adipose tissue ,CCTA ,Coronary plaque ,Young adults ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Public aspects of medicine ,RA1-1270 - Abstract
Objective: Epicardial adipose tissue (EAT) is implicated in the pathogenesis and progression of coronary artery disease (CAD). Limited data exists on the interplay between EAT and atherosclerosis in young individuals. Our study aims to explore the relationship between EAT and CAD in a young cohort. Methods: All young (18–45 years) patients without prior CAD, referred for coronary computed tomography angiography (CCTA) from 2016 to 2022 were included. EAT volume and coronary artery calcium (CAC) were calculated from dedicated non-contrast scans. Coronary plaque presence, extent, and volume were quantified from CCTA. Multivariable logistic regression models for the presence of CAD, defined as any coronary atherosclerosis, were performed. Results: Overall, 712 patients (39±4.8 years, 54 % female) with 45 % Hispanic, and 21 % non-Hispanic Black were included. Patients with CAD had higher EAT volume than those without (80.80 mL ± 36.00 vs 55.16 mL ± 27.92; P < 0.001). In those with CAC=0, higher EAT was associated with the presence of CAD compared to lower EAT volume (P < 0.001). An EAT volume >76 mL was associated with higher CAC (P < 0.001), segment involvement score (P < 0.001), and quantitative total, non-calcified, and low-attenuation plaque volumes (P < 0.002). At multivariable analysis, EAT volume (per 10 mL, OR: 1.21; 95 %CI: 1.12–1.30; P < 0.0001) was independently associated with the presence of CAD. Conclusion: In a diverse cohort of young adults without history of CAD and undergoing a clinically indicated CCTA, EAT volume was independently associated with the presence of CAD. Our findings highlight EAT potential as a novel marker for CAD risk-assessment and a potential therapeutic target in young patients.
- Published
- 2024
- Full Text
- View/download PDF
16. Omeprazol y terapia corta con tinidazol - azitromicina antihelicobacter pylori en pacientes con úlcera duodenal Omeprazole and short therapy with antihelicobacterpylori tinidazole-azithromycin in patients with duodenal ulcer
- Author
-
Roberto Pérez Menéndez, Mario J. García Ayala, Zonia Astrid Cañas Vera, Máximo J. González Torres, Hermidio Hernández Mulet, Juan A. Más Páez, and Carlos Domínguez Álvarez
- Subjects
Úlcera duodenal ,terapia corta ,omeprazol ,Helicobacter pylori ,Duodenal ulcer ,short therapy ,Medicine - Abstract
Se realizó un estudio prospectivo de 40 pacientes con úlcera duodenal infectados con Helicobacter pylori (histología y prueba de ureasa). Se trataron con 20 mg diarios de omeprazol durante 28 d; el grupo A (20 pacientes) recibió terapia corta con 500 mg de azitromicina 2 veces al día por 3 d y tinidazol 2g dosis única; el grupo B (20 pacientes), 500 mg de metronidazol 3 veces al día y 500 mg de tetraciclina 4 veces al día, ambos durante 7 d. Se investigó la infección y cicatrización de la úlcera después de mes y medio de concluido el tratamiento, mediante las mismas pruebas usadas para la inclusión del paciente en este trabajo y se tuvo en cuenta, como criterio de erradicación, la negatividad de las dos. La tasa de erradicación del grupo A (80 %) fue superior a la del grupo B (70 %). Hubo evolución clínica satisfactoria en los grupos, se obtuvo rápida mejoría de los síntomas en todos los pacientes del grupo A, sin reportarse efectos colaterales; en el grupo B, 9 pacientes refirieron como efectos secundarios más frecuentes, náuseas y sabor metálico. La cicatrización de la lesión fue del 90 % en cada grupo, se demostró fracaso en la erradicación en 2 pacientes de cada grupo con úlcera. La asociación del omeprazol y terapia corta con azitromicina y tinidazol ofrece ventajas frente al uso de este con metronidazol y tetraciclina por presentar mayor tasa de erradicación, cómoda posología y sin efectos colaterales reportados en este ensayo.A prospective study of 40 patients with duodenal ulcer infected with Helicobacter pylori (histology and urease test) was conducted. They were treated with 20 daily mg of omeprazole during 28 days. Group A (20 patients) received short therapy with 500 mg of azithromycin twice a day for 3 days and a unique dose of tinidazole 2g. Group B (20 patients) was administered 500 mg of metronidazole 3 times a day and 500 mg of tetracycline 4 times a day, both during 7 days. The infection and healing of the ulcer was investigated a month and a half after concluding the treatment by using the same tests applied for the inclusion of the patient in this study. The negativity of both was taken into account as an eradication criterion. The eradication rate of group A (80 %) was higher than that of group B (70 %). A satisfactory clinical evolution was observed in the groups. A rapid improvement of the symptoms was reported in all patients from group A, and there were no side effects. In group B, 9 patients referred to nausea and metallic taste as the most common side effects. The healing of the injury was 90 % in each group. The eradication failed in 2 patients with ulcer from each group. The association of omeprazole and short therapy with azithromycin and tinidazole offers advantages over the use of omeprazole with metronidazole and tetracycline for presenting a higher eradication rate, convenient posology and no side effects
- Published
- 2004
17. Cardiometabolic predictors of high-risk CCTA phenotype in a diverse patient population
- Author
-
Toshiki Kuno, Javier Arce, Michael Fattouh, Sharmila Sarkar, John P Skendelas, Jonathan Daich, Aldo L Schenone, Lili Zhang, Carlos J Rodriguez, Salim S Virani, Piotr J Slomka, Leslee J Shaw, Eric E Williamson, Daniel S Berman, Mario J Garcia, Damini Dey, and Leandro Slipczuk
- Subjects
High-risk plaque ,CT coronary angiogram ,Risk factors ,PCAT ,LAP ,Epicardial adipose tissue ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Public aspects of medicine ,RA1-1270 - Abstract
Introduction: Low-attenuation non-calcified plaque (LAP) burden and vascular inflammation by pericoronary adipose tissue (PCAT) measured from coronary CT angiography (CCTA) have shown to be predictors of cardiovascular outcomes. We aimed to investigate the relationships of cardiometabolic risk factors including lipoprotein(a) and epicardial adipose tissue (EAT) with CCTA high-risk imaging biomarkers, LAP and vascular inflammation. Methods: The patient population consisted of consecutive patients who underwent CCTA for stable chest pain and had a complete cardiometabolic panel including lipoprotein(a). Plaque, PCAT and EAT were measured from CT using semiautomated software. Elevated LAP burden and PCAT attenuation were defined as ≥4% and ≥70.5 HU, respectively. The primary clinical end-point was a composite of myocardial infarction, revascularization or cardiovascular death. Results: A total of 364 consecutive patients were included (median age 56 years, 64% female); the majority of patients were of Hispanic (60%), and the rest were of non-Hispanic Black (21%), non-Hispanic White (6%) and non-Hispanic Asian (4%) race/ethnicity. The prevalence of elevated LAP burden and PCAT attenuation was 31 and 18%, respectively, while only 8% had obstructive stenosis. There were significant differences in plaque characteristics among different racial/ethnic groups (p
- Published
- 2023
- Full Text
- View/download PDF
18. Imaging subclinical coronary atherosclerosis to guide lipid management, are we there yet?
- Author
-
Pamela Piña, Daniel Lorenzatti, Rita Paula, Jonathan Daich, Aldo L Schenone, Carlos Gongora, Mario J Garcia, Michael J Blaha, Matthew J Budoff, Daniel S Berman, Salim S Virani, and Leandro Slipczuk
- Subjects
Plaque burden ,Lipids ,Plaque characterization ,CAC ,CCTA ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Public aspects of medicine ,RA1-1270 - Abstract
Atherosclerotic cardiovascular disease risk (ASCVD) is an ongoing epidemic, and lipid abnormalities are its primordial cause. Most individuals suffering a first ASCVD event are previously asymptomatic and often do not receive preventative therapies. The cornerstone of primary prevention has been the identification of individuals at risk through risk calculators based on clinical and laboratory traditional risk factors plus risk enhancers. However, it is well accepted that a clinical risk calculator misclassifies a significant proportion of individuals leading to the prescription of a lipid-lowering medication with very little yield or a missed opportunity for lipid-lowering agents with a potentially preventable event. The development of coronary artery calcium scoring (CAC) and CT coronary angiography (CCTA) provide complementary tools to directly visualize coronary plaque and other risk-modifying imaging components that can potentially provide individualized lipid management.Understanding patient selection for CAC or potentially CCTA and the risk implications of the different parameters provided, such as CAC score, coronary stenosis, plaque characteristics and burden, epicardial adipose tissue, and pericoronary adipose tissue, have grown more complex as technologies evolve. These parameters directly affect the shared decision with patients to start or withhold lipid-lowering therapies, to adjust statin intensity or LDL cholesterol goals. Emerging lipid lowering studies with non-invasive imaging as a guide to patient selection and treatment efficacy, plus the evolution of lipid lowering therapies from statins to a diverse armament of newer high-cost agents have pushed these two fields forward with a complex interaction. This review will discuss existing risk estimators, and non-invasive imaging techniques for subclinical coronary atherosclerosis, traditionally studied using CAC and more recently CCTA with qualitative and quantitative measurements. We will also explore the current data, gaps of knowledge and future directions on the use of these techniques in the risk-stratification and guidance of lipid management.
- Published
- 2023
- Full Text
- View/download PDF
19. Hospital bed occupancy rate is an independent risk factor for COVID-19 inpatient mortality: a pandemic epicentre cohort study
- Author
-
Mario J Garcia, Xiaonan Xue, Omar Saeed, Snehal R Patel, Ulrich P Jorde, Andrew D Racine, Rachna Kataria, Francesco Castagna, Yoram A Puius, and Daniel B Sims
- Subjects
Medicine - Published
- 2022
- Full Text
- View/download PDF
20. Therapeutic management of hyperlipoproteinemia (a)
- Author
-
Constantine E Kosmas, Andreas Sourlas, Gordon Mallarkey, Delia Silverio, Domingo Y Ynoa, Peter D Montan, Eliscer Guzman, and Mario J Garcia
- Subjects
cardiovascular disease ,cardiovascular risk ,hyperlipoproteinemia (a) ,lipoprotein (a) ,therapeutic management ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Cardiovascular disease (CVD) has consistently been the leading cause of death worldwide. Several clinical and epidemiological studies have demonstrated that an elevated plasma concentration of lipoprotein (a) [Lp(a)] is a causative and independent major risk factor for the development of CVD, as well as calcific aortic valve stenosis. Thus, the therapeutic management of hyperlipoproteinemia (a) has received much attention, as significant reductions in Lp(a) levels may, potentially, favorably affect cardiovascular risk. Aspirin, niacin, estrogens, and statins, which act on different molecular pathways, may be prescribed to patients with mild or modest elevations of Lp(a) levels. Other therapeutic interventions, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, Lp(a) apheresis, and the novel antisense oligonucleotides APO(a)-Rx and APO(a)-LRx, which are being evaluated in ongoing clinical trials, have provided some promising results and can potentially be used in severe cases of hyperlipoproteinemia (a). This review aims to present and discuss the current clinical and scientific data pertaining to the therapeutic options for the management of hyperlipoproteinemia (a).
- Published
- 2019
- Full Text
- View/download PDF
21. Diagnostic Strategies for Early Recognition of Cancer Therapeutics–Related Cardiac Dysfunction
- Author
-
Carlos R Manrique, Michael Park, Nidhish Tiwari, Juan Carlos Plana, and Mario J Garcia
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Cardiovascular toxicity in the form of cardiac dysfunction continues to be an obstacle for patients with cancer. Survival and quality of life of cancer survivors are frequently affected by increased incidence of cardiovascular disease. The involvement of the cardiovascular system by primary or secondary malignancies, as well as its dysfunction secondary to the administration of antineoplastics, has led to the development of a new discipline called Cardio-Oncology, an exciting cardiology subspecialty with more questions than answers and as a result an enormous opportunity for research in the field. Multidisciplinary efforts have been focused on the prevention, diagnosis, and treatment of cancer therapeutics–related cardiovascular dysfunction (CTRCD). This review article will focus on the early diagnosis of left ventricular dysfunction associated with chemotherapy. Currently, the identification of cardiac toxicity associated with cancer treatment is the cornerstone for critical decisions regarding anticancer therapy and cardioprotective strategies. Its early detection, especially in subclinical phases, allows immediate intervention to prevent further impairment of the myocardium and other cardiovascular structures. The most significant published studies were selected for this revision, providing an updated document for the health professionals involved in the care of patients with cancer. We examined the current evidence and recommendations for biochemical and noninvasive diagnostic techniques, including their specific role for identification of CTRCD. Traditional and advanced imaging modalities, used alone or in combination with cardiovascular biomarkers, are essential for the recognition of cardiotoxicity during cancer therapy. Evolving basic and clinical research are focused on the development of more sensitive and specific diagnostic tools and for the recognition of cardiac toxicity.
- Published
- 2017
- Full Text
- View/download PDF
22. Stimulating myocardial regeneration with periostin Peptide in large mammals improves function post-myocardial infarction but increases myocardial fibrosis.
- Author
-
Dennis Ladage, Elisa Yaniz-Galende, Kleopatra Rapti, Kiyotake Ishikawa, Lisa Tilemann, Scott Shapiro, Yoshiaki Takewa, Jochen Muller-Ehmsen, Martin Schwarz, Mario J Garcia, Javier Sanz, Roger J Hajjar, and Yoshiaki Kawase
- Subjects
Medicine ,Science - Abstract
AIMS: Mammalian myocardium has a finite but limited capacity to regenerate. Experimentally stimulating proliferation of cardiomyocytes with extracellular regeneration factors like periostin enhances cardiac repair in rodents. The aim of this study was to develop a safe method for delivering regeneration factors to the heart and to test the functional and structural effects of periostin peptide treatment in a large animal model of myocardial infarction (MI). METHODS AND RESULTS: We developed a controlled release system to deliver recombinant periostin peptide into the pericardial space. A single application of this method was performed two days after experimental MI in swine. Animals were randomly assigned to receive either saline or periostin peptide. Experimental groups were compared at baseline, day 2, 1 month and 3 months. Treatment with periostin peptide increased the EF from 31% to 41% and decreased by 22% the infarct size within 12 weeks. Periostin peptide-treated animals had newly formed myocardium strips within the infarct scar, leading to locally improved myocardial function. In addition the capillary density was increased in animals receiving periostin. However, periostin peptide treatment increased myocardial fibrosis in the remote region at one week and 12 weeks post-treatment. CONCLUSION: Our study shows that myocardial regeneration through targeted peptides is possible. However, in the case of periostin the effects on cardiac fibrosis may limit its clinical application as a viable therapeutic strategy.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.